Tevogen Bio (NASDAQ:TVGN) Issues Earnings Results

Tevogen Bio (NASDAQ:TVGN) posted its earnings results on Friday. The company reported ($1.61) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.00) by $0.39, FiscalAI reports.

Tevogen Bio Price Performance

TVGN stock opened at $7.95 on Friday. The stock has a market capitalization of $33.07 million, a P/E ratio of -0.84 and a beta of 0.09. The business has a 50-day moving average of $6.33 and a 200-day moving average of $14.49. Tevogen Bio has a fifty-two week low of $4.14 and a fifty-two week high of $75.50.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the company. D. Boral Capital cut Tevogen Bio from a “buy” rating to a “hold” rating in a research note on Wednesday, March 4th. Weiss Ratings reissued a “sell (e+)” rating on shares of Tevogen Bio in a research note on Monday, April 20th. Finally, Wall Street Zen cut Tevogen Bio to a “strong sell” rating in a research note on Saturday, March 21st. One analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Reduce” and an average price target of $100.00.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. Deutsche Bank AG boosted its position in shares of Tevogen Bio by 304.1% during the fourth quarter. Deutsche Bank AG now owns 173,734 shares of the company’s stock worth $57,000 after buying an additional 130,738 shares during the period. Bridgeway Capital Management LLC boosted its position in shares of Tevogen Bio by 66.7% during the third quarter. Bridgeway Capital Management LLC now owns 82,500 shares of the company’s stock worth $65,000 after buying an additional 33,000 shares during the period. Finally, Goldman Sachs Group Inc. boosted its position in shares of Tevogen Bio by 126.0% during the fourth quarter. Goldman Sachs Group Inc. now owns 273,694 shares of the company’s stock worth $91,000 after buying an additional 152,572 shares during the period.

About Tevogen Bio

Tevogen Bio plc (NASDAQ:TVGN) is a clinical-stage biotechnology company focused on developing personalized natural killer (NK) cell immunotherapies for oncology and severe viral diseases. Leveraging proprietary induced pluripotent stem cell (iPSC) and donor-derived NK cell platforms, Tevogen Bio aims to create off-the-shelf cell therapy products that offer scalable and cost-efficient treatment options. The company’s lead candidate, TVGN-484, is an allogeneic NK cell therapy in clinical trials for relapsed or refractory acute myeloid leukemia (AML).

In addition to its lead program in AML, Tevogen Bio’s pipeline includes preclinical NK cell candidates directed against hematological malignancies, solid tumors and viral infections.